Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0001214659-26-007982 0001232621 XXXXXXXX LIVE 1 Ordinary Shares par value NIS 5.00 per share 07/23/2026 false 0001643303 63008G203 Nano Dimension Ltd. 60 Tower Road Waltham MA 02451 Kevin Tang 858-200-3830 4747 Executive Drive Suite 210 San Diego CA 92121 0001232621 N TANG CAPITAL MANAGEMENT, LLC WC N DE 0.00 16715812.00 0.00 16715812.00 16715812.00 N 7.9 OO Tang Capital Management, LLC ("TCM") beneficially owns 16,715,812 of the Issuer's American Depository Shares ("ADSs") which each represent one Ordinary Share of the Issuer. TCM shares voting and dispositive power over such shares with Tang Capital Partners, LP ("TCP"), Tang Capital Partners International, LP ("TCPI"), Tang Capital Partners III, Inc. ("TCP III"), Tang Capital Partners IV, Inc. ("TCP IV") and Kevin Tang. The percentages used herein are based on 210,506,899 Ordinary Shares outstanding as of June 23, 2026, as set forth in the Issuer's Schedule 14A filed on Form DEFC14A with the Securities and Exchange Commission on June 25, 2026. 0001178579 N KEVIN TANG WC N X1 0.00 16715812.00 0.00 16715812.00 16715812.00 N 7.9 IN Kevin Tang beneficially owns 16,715,812 of the Issuer's ADSs which each represent one Ordinary Share of the Issuer. Kevin Tang shares voting and dispositive power over such shares with TCP, TCPI, TCP III, TCP IV and TCM. 0001191935 N TANG CAPITAL PARTNERS, LP WC N DE 0.00 3830718.00 0.00 3830718.00 3830718.00 N 1.8 PN TCP beneficially owns 3,830,718 of the Issuer's ADSs which each represent one Ordinary Share of the Issuer. TCP shares voting and dispositive power over such shares with TCM and Kevin Tang. 0002064011 N TANG CAPITAL PARTNERS INTERNATIONAL, LP WC N DE 0.00 5223680.00 0.00 5223680.00 5223680.00 N 2.5 PN TCPI beneficially owns 5,223,680 of the Issuer's ADSs which each represent one Ordinary Share of the Issuer. TCPI shares voting and dispositive power over such shares with TCM and Kevin Tang. 0002036763 N TANG CAPITAL PARTNERS III, INC WC N NV 0.00 3830712.00 0.00 3830712.00 3830712.00 N 1.8 CO TCP III beneficially owns 3,830,712 of the Issuer's ADSs which each represent one Ordinary Share of the Issuer. TCP III shares voting and dispositive power over such shares with TCM and Kevin Tang. 0002036770 N TANG CAPITAL PARTNERS IV, INC WC N NV 0.00 3830702.00 0.00 3830702.00 3830702.00 N 1.8 CO TCP IV beneficially owns 3,830,702 of the Issuer's ADSs which each represent one Ordinary Share of the Issuer. TCP IV shares voting and dispositive power over such shares with TCM and Kevin Tang. 0001970065 N CONCENTRA BIOSCIENCES, LLC WC N DE 0.00 0.00 0.00 0.00 0.00 N 0 OO Ordinary Shares par value NIS 5.00 per share Nano Dimension Ltd. 60 Tower Road Waltham MA 02451 This Schedule 13D/A (this "Statement") amends the Schedule 13D (the "Original Schedule 13D") filed on June 30, 2026. Items 3, 5 and 7 of the Statement is hereby amended and supplemented to the extent hereinafter expressly set forth. Except as amended hereby, the original disclosure set forth in the Statement shall remain unchanged. All capitalized terms used and not expressly defined herein have the respective meanings ascribed to such terms in the Original Schedule 13D. Item 3 of the Original Schedule 13D is hereby amended to add the following: Since June 30, 2026 the Reporting Persons have expended an aggregate of approximately $3.6 million to purchase 2,422,999 of the Issuer's Ordinary Shares through the open market. The Ordinary Shares were acquired in the ordinary course of business. The information previously provided in response to Item 5 is hereby amended and restated by replacing the text thereof in its entirety with the following: The information set forth in the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5. As of the date hereof the Reporting Persons beneficially own an aggregate of 16,715,812 shares of the Issuer's Ordinary Shares, representing 7.9% of the outstanding shares. See item 5(a) above. Schedule A attached hereto as Exhibit 3 describes all transactions in the Issuer's Ordinary Shares that were effected during the past 60 days by the Reporting Persons. No person other than a Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Ordinary Shares beneficially owned by the Reporting Persons. Not applicable Exhibit 1: Joint Filing Agreement by and among the Reporting Persons (filed as Exhibit 1 of the 13D filed on June 30, 2026 by the Reporting Persons with respect to the Ordinary Shares of the Issuer). Exhibit 2: Merger Proposal, dated June 30, 2026, sent from TCM to the Issuer (filed as Exhibit 2 of the 13D filed on June 30, 2026 by the Reporting Persons with respect to the Ordinary Shares of the Issuer). Exhibit 3: Schedule A: Transactions during the past 60 days (as amended). TANG CAPITAL MANAGEMENT, LLC /s/ Kevin Tang Manager 07/27/2026 KEVIN TANG /s/ Kevin Tang Self 07/27/2026 TANG CAPITAL PARTNERS, LP /s/ Kevin Tang Manager, Tang Capital Management, LLC, General Partner 07/27/2026 TANG CAPITAL PARTNERS INTERNATIONAL, LP /s/ Kevin Tang Manager, Tang Capital Management, LLC, General Partner 07/27/2026 TANG CAPITAL PARTNERS III, INC /s/ Kevin Tang Chief Executive Officer 07/27/2026 TANG CAPITAL PARTNERS IV, INC /s/ Kevin Tang Chief Executive Officer 07/27/2026 CONCENTRA BIOSCIENCES, LLC /s/ Kevin Tang Chief Executive Officer 07/27/2026